---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022132"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:35:36.394115+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cingulate Q3 net loss $7.3M widens 78% YoY; NDA for CTx-1301 accepted with PDUFA May 31, 2026

## Summary
- Net loss $7.3M vs $4.1M in Q3 2024; operating loss $6.0M on R&D $2.8M (+99.5% YoY) and G&A $3.1M (+69.7%).
- Cash $6.1M at Sep 30, 2025; company says it needs ~$7M additional capital to fund through May 2026 PDUFA.
- FDA accepted NDA for ADHD drug CTx-1301; PDUFA target date May 31, 2026; $4.3M fee waiver granted.
- Appointed Bryan Downey as CCO; closed $6M promissory note financing with 9% interest, maturing 18 months.
- Commercial supply agreement with Bend Bio Sciences for exclusive U.S. manufacture of CTx-1301 through 2028.

## SEC filing metadata
- accession: 0001493152-25-022132
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/0001493152-25-022132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022132
- JSON: https://secwatch.observer/filing/0001493152-25-022132.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022132.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.